What is GlycoMimetics Inc Annual Net Profit?

GlycoMimetics Inc Annual Net Profit fell 2.66% in the last year to $37.88 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

What is GlycoMimetics Inc Price to Earning Ratio?

GlycoMimetics Inc Price to Earning Ratio is -0.37, which is negative.

What is GlycoMimetics Inc Stock Price?

GlycoMimetics Inc Stock Price fell 88.54% and underperformed its sector by 94.86% in the past year.

What is GlycoMimetics Inc Quarterly Net profit?

GlycoMimetics Inc Quarterly Net profit rose 20.44% YoY to $7.22 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

What is GlycoMimetics Inc Debt to Equity Ratio?

GlycoMimetics Inc Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is GlycoMimetics Inc Return on Equity(ROE)?

GlycoMimetics Inc Return on Equity(ROE) for the last financial year was -173.25%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is GlycoMimetics Inc Mutual Fund Holding?

GlycoMimetics Inc Mutual Fund Holding decreased by 0% in the last quarter to 11.81.

What is GlycoMimetics Inc Promoter Share Holding?

GlycoMimetics Inc Promoter Share Holding stayed the same in the most recent quarter at 2.67%.

What is GlycoMimetics Inc Institutional Holding?

GlycoMimetics Inc Institutional Holding increased by 0.02% in the last quarter to 47.06.

How is the GlycoMimetics Inc today?

The GlycoMimetics Inc today is trading in the down by 0.00% at 0.22.

How has GlycoMimetics Inc performed historically?

The GlycoMimetics Inc is currently trading down 0.00% on an intraday basis in the past week the index rose 10.00%. The index has been down -15.38% in the past quarter and fell -88.54% in the past year. You can view this in the overview section.

GlycoMimetics Inc XNAS: GLYC

GlycoMimetics Inc Live Share Price Today, Share Analysis and Chart

Name: GlycoMimetics Inc: Is Infosys Ltd. worth buying?
Item: GlycoMimetics Inc
Rating: 1.23958325
Author: Trendlyne DVM scores

Download real time

0.22 0.00 (0.00%)

89.27% Fall from 52W High

49,427 XNAS Volume

XNAS 21 Apr, 2025 1:32 PM (EDT)

Board Meeting

The next board meeting for GlycoMimetics Inc is on 01 May 2025 for the purpose of GlycoMimetics Inc Annual General Meeting for 2025 See details

GlycoMimetics Inc Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	14.2
PE TTM Negative PE TTM Unavailable in chosen country	-0.4
PEG TTM Below industry Median Unavailable in chosen country	0.1
Price to Book Below industry Median Unavailable in chosen country	2.7
Institutional holding current Qtr % Below industry Median Unavailable in chosen country	47.1
Revenue Growth Qtr YoY % Negative Revenue Growth Qtr YoY % Unavailable in chosen country	-100
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-100
Net Profit Qtr Growth YoY % Below industry Median Unavailable in chosen country	20.4
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-2.7
Piotroski Score Below industry Median Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-14.5
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-173.2
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-134.3

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

5.8 / 100

Technically Neutral

43.8 / 100

1Yr Price target upside is 355%

1 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

GlycoMimetics Inc Stock Price Analysis

Week Price Range 10.0% 1 Week return Unavailable in chosen country	0.2 (LTP) 0.20.2 LowHigh
Month Price Range -18.5% 1 Month return Unavailable in chosen country	0.2 (LTP) 0.20.3 LowHigh
52 Week Price Range -88.5% 1 Year return Unavailable in chosen country	0.2 (LTP) 0.12 LowHigh

View full Share Price History

GlycoMimetics Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

GlycoMimetics Inc's Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

QUARTER
ANNUAL

Current EPS

-0.1

Avg. Estimate

-0.1

Low Estimate

-0.1

High Estimate

-0.1

Current EPS

Avg. Estimate

Consensus Recommendation

1 ANALYST Recommendations

STRONG BUY

The consensus recommendation from 1 analyst for GlycoMimetics Inc is STRONG BUY

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

GlycoMimetics Inc Stock Analysis

GlycoMimetics Inc stock analysis with key metrics, changes, and trends.

GlycoMimetics Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$37.88 M	2.66%	negative	Annual Net Profit fell 2.66% in the last year to $37.88 M. Its sector's average net profit growth for the last fiscal year was -30.36%.
Price to Earning Ratio	-0.37	-	negative	Price to Earning Ratio is -0.37, which is negative.
Stock Price	$0.22	-88.54%	negative	Stock Price fell 88.54% and underperformed its sector by 94.86% in the past year.
Quarterly Net profit	$7.22 M	20.44%	positive	Quarterly Net profit rose 20.44% YoY to $7.22 M. Its sector's average net profit growth YoY for the quarter was -48.37%.
Debt to Equity Ratio	0.01	-	positive	Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-173.25 %	-173.25%	negative	Return on Equity(ROE) for the last financial year was -173.25%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	11.81 %	0%	negative	Mutual Fund Holding decreased by 0% in the last quarter to 11.81.
Promoter Share Holding	2.67 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 2.67%.
Institutional Holding	47.06 %	0.02%	positive	Institutional Holding increased by 0.02% in the last quarter to 47.06.

VIEW LESS

Loading data..

GlycoMimetics Inc - Company Profile

What does GlycoMimetics Inc do?

GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.

Gross Remuneration

2025

Gross Remuneration

Year

GlycoMimetics Inc Live Share Price Today, Share Analysis and Chart

89.27% Fall from 52W High

GlycoMimetics Inc Key Metrics

Market Capitalization

PE TTM

PEG TTM

Price to Book

Institutional holding current Qtr %

Revenue Growth Qtr YoY %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

GlycoMimetics Inc Stock Price Analysis

Week Price Range

Month Price Range

52 Week Price Range

GlycoMimetics Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

GlycoMimetics Inc's Revenue was higher than average estimate 1 time in past 1 year

EPS forecast

Consensus Recommendation

The consensus recommendation from 1 analyst for GlycoMimetics Inc is STRONG BUY

GlycoMimetics Inc Stock Analysis

GlycoMimetics Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 2.66% in the last year to $37.88 M. Its sector's average net profit growth for the last fiscal year was -30.36%.

Price to Earning Ratio is -0.37, which is negative.

Stock Price fell 88.54% and underperformed its sector by 94.86% in the past year.

Quarterly Net profit rose 20.44% YoY to $7.22 M. Its sector's average net profit growth YoY for the quarter was -48.37%.

Debt to Equity Ratio of 0.01 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -173.25%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0% in the last quarter to 11.81.

Promoter Share Holding stayed the same in the most recent quarter at 2.67%.

Institutional Holding increased by 0.02% in the last quarter to 47.06.

GlycoMimetics Inc - Company Profile

What does GlycoMimetics Inc do?

GlycoMimetics Inc Management structure

Mr. Brian M. Hahn

Principal Accounting Officer, Chief Financial Officer and Senior Vice President

Mr. Harout Semerjian

Director, President and Chief Executive Officer

Dr. Edwin Rock, M.D.

Chief Medical Officer and Senior Vice President

GlycoMimetics Inc Board of directors

Mr. Harout Semerjian

Director, President and Chief Executive Officer

Mr. Daniel M. Junius

Independent Director

Dr. Mark Alan Goldberg, M.D.

Independent Director

Ms. Patricia S. Andrews

Independent Director

Mr. Scott T. Jackson, M.B.A.

Independent Director

Mr. Timothy R. Pearson

Chairman of the Board

GlycoMimetics Inc FAQ

How is GlycoMimetics Inc today?

GlycoMimetics Inc today is trading in the red, and is down by 0.00% at 0.22.

How has GlycoMimetics Inc performed historically?

GlycoMimetics Inc is currently trading down 0.00% on an intraday basis. In the past week the stock rose 10.00%. stock has been down -15.38% in the past quarter and fell -88.54% in the past year. You can view this in the overview section.